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Asthma is a chronic airway inflammatory disease that affects ~300 million people world-
wide. It is characterized by airway constriction that leads to wheezing, coughing, and 
shortness of breath. The most common treatments are corticosteroids and β2-adren-
ergic receptor antagonists, which target inflammation and airway smooth muscle con-
striction, respectively. The incidence and severity of asthma is greater in women than in 
men, and women are more prone to develop corticosteroid-resistant or “hard-to-treat” 
asthma. Puberty, menstruation, pregnancy, menopause, and oral contraceptives are 
known to contribute to disease outcome in women, suggesting a role for estrogen and 
other hormones impacting allergic inflammation. Currently, the mechanisms underlying 
these sex differences are poorly understood, although the effect of sex hormones, such 
as estrogen, on allergic inflammation is gaining interest. Asthma presents as a hetero-
geneous disease. In typical Th2-type allergic asthma, interleukin (IL)-4 and IL-13 pre-
dominate, driving IgE production and recruitment of eosinophils into the lungs. Chronic 
Th2-inflammation in the lung results in structural changes and activation of multiple 
immune cell types, leading to a deterioration of lung function over time. Most immune 
cells express estrogen receptors (ERα, ERβ, or the membrane-bound G-protein-coupled 
ER) to varying degrees and can respond to the hormone. Together these receptors 
have demonstrated the capacity to regulate a spectrum of immune functions, including 
adhesion, migration, survival, wound healing, and antibody and cytokine production. 
This review will cover the current understanding of estrogen signaling in allergic inflam-
mation and discuss how this signaling may contribute to sex differences in asthma 
and allergy.
Keywords: estrogen, allergy, asthma, inflammation, sex difference, macrophages, iL-4 and iL-13
iNTRODUCTiON: BACKGROUND ON ALLeRGiC iNFLAMMATiON 
AND ASTHMA
Allergic disorders are characterized by Th2 responses against innocuous environmental factors 
that result in eosinophilic inflammation and the production of interleukin (IL)-4, IL-13, and IgE. 
Genetic, behavioral, sex-specific, and environmental factors contribute to the rising incidence 
of allergic diseases. Environmental factors that contribute to allergies are extremely broad and 
include a variety of food, plant, insect, and pollutant products. Allergic sensitization initiates the 
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“atopic march,” and chronic exposure to environmental insults 
at epithelial surfaces leads to the development of a spectrum of 
allergic disorders ranging from dermatitis to asthma [reviewed 
in Ref. (1, 2)]. Allergic diseases are increasingly common in the 
Western world and to date have no cure. Current treatments 
broadly include antihistamines, anticongestants, antileukot-
rienes, bronchodilators, and steroids. Th2 (IL-4, IL-13 and IL-5) 
cytokine-neutralizing antibodies are currently in phase II and 
phase III of clinical trials with promising results (3–6). However, 
hard-to-treat allergies limit the effectiveness of current therapies, 
especially in the case of asthma.
Asthma is an allergic inflammation of the respiratory tract 
that affects >300 million people worldwide. It has a prevalence 
of 1 in 12 adults and 1 in 11 children (7, 8). Respiratory inflam-
mation associated with asthma leads to fibrosis and airway con-
striction, which presents as wheezing and shortness of breath. 
The epithelium serves as the interface between allergens and the 
underlying immune system and thus initiates inflammation by 
secreting cytokines and chemokines such as IL-5, regulated on 
activation, normal T cell expressed and secreted (RANTES or 
CCL5), IL-22, IL-25, thymic stromal lymphopoietin (TSLP), and 
IL-33 [reviewed in Ref. (9)]. Th2-polarized T cells are abundant 
in the draining lymph nodes of the lungs, circulating blood, and 
bronchoalveolar lavage (BAL) of patients with asthma- and aller-
gen-challenged mice. They are central to orchestrating inflam-
mation by secreting cytokines, such as IL-4, IL-5, IL-13, and 
granulocyte macrophage colony-stimulating factor (GM-CSF). 
The BAL of asthmatic patients and allergen-challenged mice 
contains abundant eosinophils and M2-polarized macrophages, 
which together secrete a variety of inflammation-promoting 
factors (10–12) [reviewed in Ref. (13)]. These factors include 
chemokines that recruit more lymphocytes into the airways, 
prostaglandins that promote bronchoconstriction, and matrix 
metalloproteinases (MMPs) that promote fibrotic tissue remod-
eling. Histologically, the airways are infiltrated by leukocytes, 
and the surrounding smooth muscle is thickened from enhanced 
collagen deposition. In hard-to-treat cases of steroid-resistant 
asthma, neutrophils infiltrate the BAL as a result of Th17 
responses and IL-8 production.
Asthma incidence and severity exhibit sex differences, and 
there is mounting clinical and animal model evidence that impli-
cates sex hormones, particularly estrogen, in being key mediators 
of these differences [reviewed in Ref. (14)]. In the following sec-
tions, we will summarize these sex differences in clinical asthma 
in humans and elaborate on the effects of cycling estrogen levels 
on asthma severity and incidence in women. Although other sex 
hormones such as androgens and progesterone influence the 
immune system and the action of estrogen in cells, we will focus 
this review on the studies of estrogen on the immune system. Our 
emphasis here will be the effect of estrogen on innate immune 
cells, with some discussion of the adaptive immune system. We 
will describe the estrogen receptors (ERs) and their regulation of 
gene expression. We will then review recent insights from animal 
models regarding the impact of estrogen signaling on allergic 
inflammation, the various cell types involved, and how this may 
account for the sex difference observed in asthma.
iNCiDeNCe OF ASTHMA AND ALLeRGY 
iS GReATeR AMONG wOMeN THAN MeN: 
SeX DiFFeReNCeS iN ASTHMA
The onset and severity of asthma and allergies typically exhibit sex 
differences, although the results of clinical surveys differ some-
what depending on geography, likely highlighting environmental, 
cultural, and dietary factors. Virtually all atopic allergies affect 
boys more than girls in childhood. Numerous studies that have 
focused on questionnaire-based and clinician-diagnosed school 
children with atopic dermatitis have reported a male-dominant 
incidence that persists from birth until 6–11 years of age (15–17). 
Conversely, a Danish study reported that while the onset of atopic 
dermatitis was slightly delayed in girls (2.5 years of age) compared 
to that in boys (2  years of age), the overall prevalence did not 
differ by sex (18). The perceived prevalence of peanut allergy in 
Great Britain exhibits female predominance in general, although 
after age 15, that trend is reversed (19). A Norwegian study found 
girls exhibit a higher incidence of food allergies than boys after 
18  months of age (20). Allergic rhinoconjunctivitis seems to 
preferentially affect males beyond the age of 13 (21). The onset of 
puberty, however, reverses that trend for most allergic disorders, 
including asthma (22). Women over the age of 25 account for 
>62% of hospitalizations due to acute asthma attacks and, in 
2009, accounted for 64% of asthma-related deaths (23, 24). 
Roughly 40% of women experience premenstrual exacerbations 
of asthma and women are more likely to be non-responsive to 
corticosteroid therapy (25, 26).
Asthma symptoms in women seem to change with various life-
stage factors such as menstruation, pregnancy, and menopause 
(27–30). The incidence of allergy and asthma peaks in women 
after puberty and strongly subsides with age (31). Roughly 
33–52% of asthmatic women report premenstrual worsening of 
symptoms (32–35). Almost 50% of women hospitalized for asthma 
symptoms are identified as premenstrual (36). Furthermore, 
spikes in menstrual hormones correlate with impaired peak 
expiratory flow rate and thus reduced lung function (37). Lung 
function is generally worse during the late follicular phase, 
when estrogen levels are highest (38). Abrupt estrogen spikes 
are alleviated with oral contraceptive use, which was shown to 
stabilize asthma symptoms in women (39). Yet, the worsening 
of symptoms with oral contraceptive use has also been reported 
(40). Pregnancy causes a large increase in circulating estrogen 
that starts with ovum fertilization and falls to prepregnancy levels 
shortly after delivery. Approximately 70% of asthmatic women 
report alleviation of symptoms during pregnancy (28, 35, 41–43). 
Symptom severity seems to return to normal within 3  months 
postpartum. Interestingly, postpartum symptom severity wors-
ens with increasing number of births (44). Estrogen levels drop 
during menopause and are lower in asthmatic women than in 
healthy women (45). Menopause typically results in exacerbated 
asthma symptoms and leads to the development of new asthma 
in previously unaffected women (46). Hormone replacement 
therapy (HRT) increases estrogen levels and alleviates symptoms 
in postmenopausal asthmatic women (45). However, HRT use 
has also been linked to a 19% increased risk of hospitalization per 
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year of use in menopausal women with asthma (47). Furthermore, 
rates of new asthma diagnosis have been reported to increase after 
HRT initiation but diminish with cessation of HRT (48). Because 
asthma comprises several distinct endotypes, this likely contrib-
utes to the seemingly conflicting outcomes of oral contraceptive 
and HRT use in women.
These survey studies collectively suggest that estrogen levels 
correlate with symptom severity and likely contribute to sex dif-
ferences in asthma. In general, women have a greater incidence 
and severity of asthma than do men (49–51). However, the 
alleviation of symptoms in women during stages of life that are 
accompanied by high levels of circulating estrogen suggests that 
the inflammatory function of estrogen may be dose-specific. This 
idea is echoed in in vitro and animal studies covered later in this 
review. To understand how estrogens impact the immune system, 
we will first give some background on ER biology in the next 
section.
eSTROGeN ReCePTOR BiOLOGY AND 
iSOFORMS
Estrogen signaling regulates reproductive physiology and gene 
expression in many tissues and cell types. Not surprisingly, the 
failure to regulate estrogen signaling is associated with a variety of 
human diseases, including breast and endometrial cancer, cardio-
vascular disease, osteoporosis, and Alzheimer’s disease [reviewed 
in Ref. (52)]. Like all hormones, estrogen readily penetrates the 
cell membrane. In the cytosol, it encounters ERs, triggers their 
dimerization, and liberates them from an inactive complex with 
heat shock protein (HSP)90 (53). The ERs then translocate to the 
nucleus and engage estrogen response elements (EREs) on target-
gene promoters (53). However, this signaling network exhibits 
several layers of regulatory complexity that result in pleiotropic 
effects on various tissues and cell types. This diversity in the 
biological functions of estrogen is achieved through the expres-
sion of several ER isoforms that have the capacity to interact with 
various transcriptional coactivators and corepressors as well as 
transcription factors to elicit an array of cellular responses. In 
fact, estrogen is known to elicit non-genomic effects on cells via 
membrane-bound receptors that crosstalk with an array of cel-
lular signaling networks (54, 55). Furthermore, phosphorylation 
of the nuclear ERs can mimic ligand binding and thus induce 
ligand-independent responses (56–58). In the following section, 
we will discuss the current understanding of the estrogen signal-
ing pathway.
The nuclear ERs exist in two main isoforms termed ERα 
and ERβ, which are part of a large superfamily of type I nuclear 
receptors. The nuclear receptor superfamily members exhibit a 
conserved structure consisting of regions A–F (Figure 1). ERα 
and ERβ both contain an N-terminal activation function-1 
(AF-1) domain within regions A and B, a zinc-finger containing 
a DNA-binding domain in the centrally located region C, and 
a C-terminal AF-2 domain within regions E/F that facilitates 
dimerization, association with Hsp90, and ligand binding via 
the ligand-binding domain (59). Region D consists of a hinge 
between the N- and C-terminal halves of the receptor. In the 
absence of ligand, ERα and ERβ are bound to heat shock proteins 
that restrict their activity. Ligand binding, however, releases the 
receptors from this complex and allows their engagement of 
target gene promoters. Several serine and tyrosine residues on 
the receptors are also subject to phosphorylation that enhances 
receptor activity [reviewed in Ref. (60)]. Upon ligation, the DNA-
binding activity of the AF-1 domain and the dimerization activity 
of the AF-2 domain facilitate transcriptional regulation through 
recruitment of >40 different coactivators, including histone 
acetyltransferases, ubiquitin ligases, arginine methyltransferases, 
and transcription factors.
Estrogen receptor α consists of the full-length 66 kilodalton 
(kDa) isoform and alternatively spliced truncated 36 and 46 kDa 
isoforms that result from internal ATG transcription start 
codons. The 46 kDa isoform lacks the AF-1 domain, and 36 kDa 
isoform lacks both the AF-1 and AF-2 domains preventing 
efficient transcriptional activity but permitting heterodimeriza-
tion with the full-length receptor (61, 62). Human macrophages 
primarily express the 46 kDa isoform of ERα and to a lesser extent 
the full-length 66 receptor and the 46 kDa isoform is estrogen 
inducible (63). Furthermore, the transition of monocytes along 
the monocyte-macrophage axis is accompanied by an upregula-
tion of the 46 kDa ERα (63). Both isoforms can localize to the 
membrane. The 5′ flanking region of the 36 kDa isoform contains 
several putative transcription factor-binding sites, including 
NF-κB, glucocorticoid receptor (GR), specificity protein (SP)1, 
and activator protein 1, but is suppressed by full-length 66 kDa 
ERα (64). ERα-36 is the only ERα isoform expressed in human 
peripheral blood monocytes and suppresses proinflammatory 
cytokine production in response to LPS (65). Other truncated 
isoforms have been identified in a variety of human cancers and 
rat cells although their expression in healthy human tissue is 
poorly understood (66, 67). ERβ consists of at least five different 
truncated isoforms that lack either the AF-1 or AF-2 domain.
TRANSCRiPTiONAL ReGULATiON BY eRs
The conventional linear pathway of nuclear receptor signaling 
whereby ligated hormone receptors regulate gene expression at 
well-defined promoter elements has been revised in recent years. 
FiGURe 1 | estrogen receptor isoforms. The domain organization of 
human estrogen receptor α and β isoforms are illustrated above. The size of 
the full-length, truncated, and elongated isoforms is indicated.
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When bound to ligand, ERα and ERβ form either homo- or het-
erodimers and engage EREs on target gene promoters [reviewed 
in Ref. (68)]. Intriguingly, although EREs can be functional even 
as far as 2 kilobases (kb) from their target promoter and exhibit 
activity either upstream or downstream from the target gene, 
approximately one-third of estrogen-regulated genes in humans 
lack EREs altogether (69). Rather, association of ERs with SP-1 
mediates indirect ER–DNA binding and utilizes the coactivator-
recruiting activity of ERs to drive gene expression independently 
of EREs. This form of ERE-independent gene induction has been 
identified for low-density lipoprotein receptor, endothelial nitric 
oxide synthase (eNOS), c-fos, cyclin D1, and the retinoic acid 
receptor 1α (70–74). Other transcription factors, such as NF-κB, 
c-jun, and cyclic adenosine monophosphate (cAMP) response 
element-binding protein have also been shown to recruit ERs for 
ERE-independent sites (75). Interestingly, human ERα and ERβ 
seem to have opposing effects on these promoters, with ERα-
enhancing and ERβ-repressing gene expression. This phenom-
enon may reflect a defective AF-1 domain in human ERβ (76).
The canonical steroid receptor coactivator (SRC) family asso-
ciated with ERs is termed the SRC/p160 family. The members 
of this family are referred to by various names in the literature 
but consist of SRC-1 (also termed NCoA-1), SRC-2 (also termed 
TIF2, GRIP1, or NCoA-2), and SRC-3 (also termed RAC3, pCIP, 
ACTR, AIB1, TRAM-1, or NCoA-3). These coactivators contain 
a nuclear receptor box that consists of an LXXLL motif that fits 
within the hydrophobic groove formed by the 12 α-helices of the 
AF-2 domain (77). Unligated or tamoxifen-bound ERs can also 
interact with nuclear receptor corepressors N-CoR and SMRT, 
which inhibit the recruitment of SRC/p160 and thus repress 
transcription at ERE sites (78).
POST-TRANSLATiONAL  
MODiFiCATiONS OF eR
Estrogen receptor α and ERβ contain conserved serine residues 
that are phosphorylated in response to ligand binding as well as 
independently of ligand binding. Serines-104, -106, and -118 have 
been shown to be phosphorylated by cyclin-dependent kinases 
after estrogen binding (79). These sites reside within the AF-1 
domain and enhance ER activity. In addition, ligand-independent 
activation of the ERs by growth factors and cyclic AMP has been 
described. In fact, Erk1/2 can directly phosphorylate serines-104 
and -118 within the AF-1 domain of ERα and induce dimerization 
and activation in response to either epidermal growth factor or 
estrogen signaling (60, 80, 81). Ribosomal S6 kinase and protein 
kinase B (Akt) have been shown to phosphorylate serine-167 in 
response to growth factor signaling (82, 83). Protein kinase A 
activation and cAMP treatment of cells lead to phosphorylation 
of serine-236, which resides within the DNA-binding domain 
(84, 85). A tyrosine residue (Tyr-537) within the AF-2 domain 
is also phosphorylated in ERs and serves as a docking site for 
the Src homology-2 domain of c-Src (86). The general outcome 
of these phosphorylation events is enhanced receptor activity. 
Several groups have compared mutants with alanine substitutions 
at these serine sites to wild-type receptors using ERE reporter 
assays and found that the inability to phosphorylate these sites 
translates to impaired target gene expression (56, 80, 87, 88).
Estrogen receptors not only regulate reproductive and 
developmental physiology but also participate in hormone-
independent signaling by interacting with growth factor and 
other cell-signaling networks. As described earlier, ER signaling 
is regulated by several factors, including the relative abundance 
of receptor isoforms, interactions with coactivators/corepressors, 
and DNA-remodeling proteins, receptor phosphorylation, and 
inputs from other signaling networks. This variety in regulation 
permits profound functional versatility and provides an avenue 
for hormonal influence over many biological pathways and 
processes, like allergic inflammation. More research is required 
to ultimately understand how ER signaling interacts with 
non-hormonal pathways. With respect to asthma, there is an 
imperative for greater understanding of the pathophysiology of 
various endotypes that comprise the disease so that the potential 
contribution of ER signaling and gene induction can be clarified.
eFFeCT OF eSTROGeN ON THe iNNATe 
iMMUNe SYSTeM
In the last few decades, our understanding of the profound effect 
of sex hormones on leukocyte biology has expanded dramatically 
[reviewed in Ref. (89)]. Castration and hormone replacement 
studies in mice have been instrumental in connecting anecdotal 
evidence of sex differences in humans to the underlying cellular 
mechanisms. Cell-specific knockout mice have provided the 
essential tools to isolate the role of individual ER isoforms and 
dissect their involvement in the inflammatory process. Studies in 
selective ER knockout animals have revealed a complex interplay 
between receptor isoforms, sex hormone levels, cell types, and 
biological outcomes. The following section will summarize the 
current understanding of estrogen signaling in cells of the innate 
immune system that are relevant to the pathogenesis of allergic 
inflammation in the lung during asthma.
MACROPHAGeS
In recent years, the role of macrophages in allergic inflam-
mation has garnered increased attention. In asthma, alveolar 
macrophages have emerged as important cellular mediators of 
inflammation and tissue remodeling [reviewed in Ref. (90–92)]. 
Allergic asthma is considered to be a Th2 disease and is thus 
accompanied by IL-4/13-polarized M2 alveolar macrophages in 
the airways. Intratracheal instillation of alternatively activated 
M2 macrophages prior to ovalbumin (OVA) challenge results in 
enhanced eosinophil and effector T cell infiltration into the BAL 
in mice (93). Macrophage depletion studies have revealed a dual 
role for alveolar macrophages in eliciting and containing allergic 
lung inflammation in mice (94). Resident alveolar macrophages 
are inherently immunosuppressive and secrete anti-inflammatory 
factors, such as transforming growth factor β (TGFβ) and IL-10 
(95, 96). In the allergic setting, however, the bronchoalveolar 
space is infiltrated by inflammatory M2-polarized macrophages 
FiGURe 2 | effects of estrogen in vitro on macrophages. The effects of estrogen on macrophages from various tissues are illustrated above. The findings of 
several studies are summarized and referenced in the figure. The effects of estrogen on proinflammatory mediators are highly dependent on the tissue of origin. 
There is a general lack of data focusing on the impact of estrogen signaling on alveolar macrophages, indicated by the question marks.
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that facilitate inflammation by secreting chemokines, such as 
chemokine c–c motif ligand 2 (CCL2), CCL17, Ym1, and found 
in inflammatory zone 1 (Fizz1 or Relmα) (97). Depletion of 
these macrophages in mice results in impaired IL-5 production, 
eosinophil influx, and airway remodeling (97). In the house, 
dust mite model of mouse allergic lung inflammation, female 
mice have more M2-like (Ym1+) cells, whereas males have more 
M1-like (interferon regulatory factor 5) cells in histological 
lung cross-sections (98). Likewise, female mice exhibit more 
eosinophils, effector T cells, and M2-polarized macrophages in 
the lungs than do males in the OVA model of lung inflamma-
tion (93). Furthermore, the production of lipid inflammatory 
mediators like leukotrienes via 5-lipoxygenase is enhanced in 
female leukocytes compared to that in male leukocytes, but this 
difference is due to suppression of the pathway by testosterone 
(99). This central role of macrophages in allergic lung inflam-
mation has warranted studies addressing the potential influence 
of sex hormones on macrophage polarization and inflammatory 
cytokine production.
Bone marrow-derived macrophages (BMMs) have served as a 
proxy in vitro model for studies addressing the effect of estrogen 
on macrophage biology. Several groups have measured mac-
rophage cytokine production in response to interferon γ (IFNγ) 
or IL-4 in the context of either exogenous estrogen treatment or 
macrophages from ER knockout mice (Figure 2). IL-4-induced 
M2 polarization is enhanced with the addition of exogenous 
estrogen at micromolar doses in mouse BMMs (100). Estrogen 
not only increases arginase 1 (Arg1) activity and Fizz1 expres-
sion in IL-4-polarized BMMs but also suppresses inducible NOS 
(iNOS) expression in IFNγ/lipopolysaccharide (LPS)-treated 
BMMs. Furthermore, these effects were determined to be medi-
ated through ERα signaling, as they were mimicked with propyl 
pyrazole triol (PPT), a selective ERα agonist, and not diarylpro-
pionitrile (DPN), a selective ERβ agonist. Likewise, BMMs from 
LysM-CRE ERαflox/flox mice fail to upregulate Arg1 and Fizz1 in 
response to IL-4 and exhibit enhanced iNOS responses to IFNγ/
LPS. Physiological doses of estrogen (picomolar to nanomolar 
range) suppress LPS-induced tumor necrosis factor α (TNFα) 
expression in mouse BMMs (101). BMMs from ovariectomized 
(OVx) mice exhibit decreased TGFβ1 mRNA, but exogenous 
treatment with estrogen rescues this phenotype, suggesting that 
estrogen may contribute to tissue remodeling in allergic inflam-
mation through TGFβ1 induction (102).
Studies addressing estrogen signaling in splenic, wound-
derived, and peritoneal macrophages have revealed heterogene-
ity in responses between macrophages obtained from different 
sources (Figure 2). Signaling through ERα with 1 μM PPT in 
murine wound-derived macrophages enhances M1 (iNOS and 
TNFα) and M2 (Arg1 and Ym1) responses following polariza-
tion with IFNγ/LPS and IL-4, respectively (100). Conversely, 
signaling through ERβ with 1 μM DPN has the opposite effect 
on M1 and M2 wound-derived macrophages. Thioglycollate 
elicitation of peritoneal macrophages is impaired in OVx mice 
replenished with estrogen (103). However, these thioglycollate-
elicited macrophages in estrogen-replenished OVx mice are 
proinflammatory in nature and express more IL-1β, IL-6, 
iNOS, and TNFα than do cells from OVx mice. These effects 
of estrogen were determined to arise from ERα-mediated 
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inhibition of phosphoinositide 3-kinase. Splenic macrophages 
treated with lower doses of estrogen (picomolar range) exhibit 
impaired LPS-induced TNFα production compared to that 
in untreated cells. These studies highlight a lack of uniform-
ity in study design but also suggest that macrophages exhibit 
heterogeneity with respect to estrogen signaling. Furthermore, 
macrophage subsets found from different tissue sources exhibit 
unique phenotypes, complicating our ability to relate studies 
that use mouse BMMs or peritoneal and splenic macrophages 
to alveolar macrophage biology (104, 105). Thus, more in vivo 
studies are needed that examine the effect of estrogen on alveo-
lar macrophages in the setting of allergic inflammation. A stable 
mouse or human alveolar macrophage cell line from would also 
provide a more appropriate in  vitro model for understanding 
lung inflammation.
DeNDRiTiC CeLLS
Dendritic cells (DCs) are essential initiators of the adaptive 
immune responses that facilitate sensitization to allergens. 
Estrogen is intricately involved in DC function from differentia-
tion to maturation and proinflammatory cytokine production. 
GM-CSF-induced DC differentiation from mouse bone marrow 
precursors is dramatically impaired when conducted using 
hormone-free serum in the culture medium (106). Adding 
estrogen (picomolar range) into the culture medium of these 
cells restores DC differentiation and responsiveness to LPS, as 
well as their capacity for T cell priming. Bone marrow from 
ERα−/− mice is defective in generating DCs with GM-CSF, 
although the addition of 10 nm estrogen partially resolved that, 
suggesting that other ERs are also important in DC differentia-
tion (106). In fact, GM-CSF-generated bone marrow-derived 
CD11b+CD11c+ DCs express both ERα and ERβ (107). A 
CD11c+CD11bint subset that emerges from 100 pM estrogen-
enhanced GM-CSF-generated bone marrow-derived DCs 
expresses langerin and exhibits other features of Langerhans’ 
cells (107). Thus, estrogen has an enhancing effect on DC dif-
ferentiation from myeloid progenitors.
The effects of estrogen on DC maturation and cytokine 
production have been addressed in several in vitro and in vivo 
models. Upon encountering pathogen-associated molecular 
patterns (PAMPs), DCs mature by downregulating endocytosis 
and upregulating the antigen presentation apparatus along with 
cytokine production. Human plasmacytoid DCs (pDCs) exhibit 
profound sex differences when stimulated with the toll-like 
receptors 7/8 ligand R-848 with pDCs obtained from premeno-
pausal women being more responsive by expressing IFNα and 
TNFα compared to age-matched males (108). Estrogen therapy 
in menopausal women dramatically increased the cytokine 
responsiveness of blood pDCs to TLR ligation, and this was 
recapitulated in an OVx mouse model (108).
Plasmacytoid DCs are known to be potent Th2-priming 
antigen-presenting cells, and they are more abundant in the 
blood of patients with asthma compared to healthy individu-
als (109, 110). IL-4-mediated depletion of pDCs is impaired in 
patients with asthma compared to healthy controls, despite no 
measurable difference in IL-4Rα expression (109). Conversely, 
pDCs also drive tolerance to allergens in OVA-challenged mice, 
and their depletion exacerbates eosinophil influx and tissue 
remodeling in the lung (111). Further, the adoptive transfer 
of pDCs back into depleted mice rescues this exacerbation. 
The adoptive transfer of pDCs cultured with house-dust mite 
allergen into mice results in an expansion of FoxP3+ Tregs as 
well as IL-10 production following allergen challenge (112). 
Human monocyte-derived DCs treated with ~70 μM estrogen 
exhibit induction of MCP-1, IL-8, and IL-6 but an unaltered 
immature phenotype with respect to major histocompatibility 
complex II (MHCII) and costimulatory molecule expression 
(113). Splenic DCs, however, respond to estrogen (10 nM – 1 
μM) by upregulating CD40 and MHCII (114). At high doses 
(in the micromolar range), estrogen downregulates endocytosis 
in splenic DCs and promotes survival as well as IL-6 and IL-10 
productions. Likewise, estrogen enhances T-cell proliferation in 
culture with LPS-activated DCs, suggesting that it promotes the 
capacity of mature DCs to stimulate T-cell responses. Further, 
estrogen treatment (1 nM) of mouse bone marrow enhances 
GM-CSF-induced DC differentiation and LPS/CpG-induced 
IL-12 production (115). In vivo experiments that focus on the 
effects of estrogen on DC-mediated T-cell priming are lacking. 
However, one group found that administration of estrogen to 
OVx mice enhanced Th1 responses to a subcutaneous OVA 
challenge and that the response required ERα expression in the 
hematopoietic compartment (116). The adoptive transfer of 
estrogen-treated DCs (~73 nM) was shown to alleviate inflam-
mation in experimental allergic encephalomyelitis (EAE) (117). 
In that model, estrogen administration in Lewis rats impaired 
the capacity of DCs to prime Th1 and Th2 T-cell response.
Like macrophages, these studies suggest that estrogen has dif-
fering effects on DCs, depending on their tissue of origin as well as 
the species being studied. Bone marrow- and monocyte-derived 
DCs exhibit enhanced inflammatory cytokine production and 
toll-like receptor ligand responsiveness with estrogen treatment. 
In splenic DCs, estrogen promotes the capacity for T-cell priming. 
In the EAE model, however, DC function seems to be less inflam-
matory with estrogen treatment (118). More studies are needed 
to discern the various dose-dependent effects of estrogen on DC 
subsets from different tissues. Studies in asthma are particularly 
important because lung DCs have a major role in priming T cells 
against allergens (119, 120).
eOSiNOPHiLS
Eosinophils are a hallmark cell type of allergic inflammation. 
These cells are recruited from the blood by IL-5, which is produced 
in response to epithelial TSLP, IL-25, and IL-33. Eosinophils are 
recruited as mature cells and elicit antihelminth immunity and 
inadvertent tissue damage by degranulation. Eosinophil gran-
ules contain several different effector molecules. Major basic 
protein, eosinophil peroxidase, eosinophil cationic protein, and 
eosinophil-derived neurotoxin are among the granular content 
of eosinophils. They have both distinct and overlapping effects 
on target cells. In general, these granular proteins exert toxic 
effects on target cells by a variety of mechanisms, including 
pore formation, ribonuclease activity, and the production of 
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FiGURe 3 | Current model for estrogen signaling in polarization in 
macrophages in the setting of allergic lung inflammation. The general 
consensus is that estrogen enhances M2 polarization while suppressing 
M1-polarization in macrophage. However, mechanistic insights are lacking, 
and questions remain regarding the interface of ERα and IL-4 signaling.
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reactive oxygen species. Eosinophils are also significant sources 
of cytokines, such as IL-4 and IL-13, and thus promote allergic 
inflammation once these cytokines are released.
Estrogen has been shown to regulate eosinophil migration, 
adhesion, survival, and degranulation. Its influence on eosino-
phil biology became clear as early as the 1960s, when it was first 
reported to induce eosinophilic infiltration into the rat uterus 
as a hallmark of uterine development and tissue remodeling 
(121–123). Additionally, the number of eosinophils in the uterus 
was found to follow the estrous cycle, peaking at the estrus phase 
and dipping at the diestrus phase (124). Uterine eosinophils are 
virtually absent from OVx animals and late in pregnancy.
Eosinophils are a key cell type involved in the pathogenesis 
of asthma and allergy and are known to express ERα and mem-
brane-bound G-protein-coupled receptor (GPR-1) in mice and 
humans (125, 126). The sex differences associated with allergic 
inflammation, and in particular asthma, are most apparent with 
the varying degrees of eosinophilia in asthma models in male and 
female mice. Female mice exhibit greater eosinophilic infiltration 
into the bronchoalveolar and parenchymal spaces than do male 
mice, coincident with increased allergen-specific IgE, increased 
cluster of differentiation 4 (CD4)+ T- and B-cell accumulation, 
and impaired lung function (127, 128). Treatment of allergen-
challenged mice with ERα antagonists, such as tamoxifen and 
ICI 182,780, dramatically reduces BAL eosinophil numbers and 
Th2 cytokines, such as IL-5 and IL-13 (125, 129). Furthermore, 
exogenous estrogen dose dependently induces both IL-5 and 
IL-13 in mediastinal lymph node cultures from allergic animals. 
Intriguingly, ovariectomy prior to OVA sensitization impairs 
eosinophil influx, which is restored with exogenous estrogen 
(129). However, ovariectomy of mice after sensitization to OVA 
exhibit enhanced eosinophilia, suggesting that estrogen may on 
the one hand promote T-cell priming against allergens but on the 
other control eosinophil infiltration after challenge. Conversely, 
Dimitropoulou et  al. (130) reported a dose-dependent reduc-
tion in eosinophil infiltration into the BAL of estrogen-treated, 
OVA-challenged, OVx mice. These discrepancies may reflect 
differences in experimental approaches and doses of estrogen 
replacement used. Estrogen administration triggers eosinophil 
degranulation in rats in  vitro and in  vivo (131). Although in a 
model of acute thioglycollate-induced sterile peritonitis, estrogen 
plays an inhibitory role in eosinophil influx and survival in mice 
(132). The administration of estrogen in OVx mice reduces 
peritoneal eosinophils and IL-5 production in this model, and 
these are restored in ERα gene knockout mice. Furthermore, 
administration of the GPR-1 agonist, G-1, to C57BL/6 and 
BALB/c mice subjected to an OVA-induced allergic inflammation 
model reduces lung eosinophilia, IL-5, and eotaxin production 
through induction of IL-10 (133). However, human eosinophils 
exhibit enhanced eotaxin-induced chemotaxis and survival with 
G-1 treatment (113). Thus, estrogen impacts eosinophils in dif-
ferent ways depending on the receptors engaged, the species used, 
the tissue in which the signaling is taking place, and whether the 
cells are analyzed in vivo or in vitro. Some of the known effects of 
estrogen on eosinophils that would increase allergic inflamma-
tion are summarized in Figure 3.
MAST CeLLS
Mast cells are detectable in the sputum of asthmatic patients, 
but sex differences with respect to mast cell function have not 
been adequately explored (134). Nevertheless, their numbers 
increase and decrease in female reproductive tissues with the 
estrous cycle, suggesting that estrogen regulates mast cell migra-
tion and biology. Mast cells from rat and human cell lines as 
well as mouse bone marrow-derived mast cells express ERα but 
not ERβ (135). In rat mammary glands, mast cells accumulate 
during the estrus and diestrus phases of the estrous cycle (136). 
After ovariectomy, mast cells decrease dramatically, but their 
numbers are restored with estrogen replacement. Estrogen 
induces IgE-dependent and -independent mast cell degranula-
tion in rats (135, 137). These effects are dependent on Ca2+ and 
thus are non-genomic although the expression of GPR-1 was not 
evaluated in this study. Mouse models of lung allergen challenge 
clearly suggest that mast cells orchestrate inflammation, but they 
do not accumulate in BAL (138). To our knowledge, no studies 
have investigated the effect of sex on the contribution of mast 
cells to allergic inflammation in mice.
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AiRwAY ePiTHeLiAL CeLLS
The airway epithelium provides front-line defense against invading 
pathogens and environmental insults in the lung by balancing gas 
exchange with innate immune function. Airway epithelial cells 
express pattern recognition receptors that enable them to detect 
and respond to PAMP and danger-associated molecular pattern 
by secreting cytokines and chemokines to drive inflammation. In 
asthma, the airway epithelium recruits innate and adaptive immune 
cells via cytokines, such as IL-25 and IL-33, and chemokines, such 
as CCL2, CCL17, and CCL20. Furthermore, these cells secrete 
TGFβ, which promotes tissue remodeling. Human bronchial 
epithelial cells express both ERα and ERβ and are responsive to 
estrogen exposure. Treatment of these cells with 10 nM estrogen 
induces endothelial NOS expression and nitric oxide production 
that results in bronchodilation (139). Similarly, the same dose of 
estrogen relaxes human airway smooth muscle and thereby induces 
bronchodilation (140). Estrogen replacement in OVx mice signifi-
cantly reduces acetylcholine responsiveness (141). These studies 
suggest that estrogen is protective against airway constriction and 
thus may be therapeutic in asthma. However, estrogen treatment of 
human airway epithelium also induces MUC5B secretion, which 
may contribute to airway lumen obstruction (142).
Currently, very little is known regarding the effect of estrogen 
on proinflammatory cytokine production by airway epithelial 
cells. In patients with cystic fibrosis, estrogen treatment reduces 
epithelial IL-8 production, which is thought to predispose women 
to Pseudomonas infection (143). Thus, estrogen may be a double-
edged sword with respect to its bronchodilation and inflamma-
tory properties. The outcome on lung function is likely the net 
result of a balance between increased allergic inflammation and 
smooth muscle relaxation/increased bronchodilation.
eFFeCT OF eSTROGeN ON THe 
ADAPTive iMMUNe SYSTeM
Estrogen signaling has profound effects on adaptive immunity. 
Consequently, women are generally at greater risk than men 
for pathology associated with immune responses to infection, 
autoimmune diseases, and allergies. The underlying cellular basis 
for these sex differences is currently being evaluated. Estrogen 
signaling is known to be important for thymic development 
and antibody production, although pregnancy levels of estrogen 
induce thymic attrition and suppress proinflammatory responses 
in mice and humans (144, 145). Thus, physiological estrogen 
levels can be functionally grouped into several categories that 
reflect various developmental stages of life. Concentrations of 
circulating estrogen vary between 40–152 pM and 1–150 nM in 
menopausal and pregnant women, respectively [reviewed in Ref. 
(14)]. Research approaches, including ER knockout, overiectomy 
of animals followed by estrogen replacement, and comparisons 
of estrogen responses in healthy and diseased lymphocytes, have 
provided important insights into the cellular basis for sex differ-
ences. This section will briefly summarize our current under-
standing of how estrogen signaling affects T and B lymphocytes 
and the consequences that may contribute to sex differences in 
health and disease.
T CeLLS
The effects of estrogen on T cells are complex and context and dose 
specific. As discussed later, estrogen has the capacity to enhance 
Th1, Th2, and Treg responses. At concentrations found during 
pregnancy (1–150 nM), estrogen promotes IFNγ production by 
CD4+ T cells. At those same concentrations, estrogen enhances ex 
vivo production of IL-10, IFNγ, and TNFα by proteolipid-specific 
CD4+ T cells from patients with multiple sclerosis compared to 
that by cells from healthy patients and cells exposed to proteolipid 
alone (146). Interestingly, higher doses of estrogen seem to inhibit 
TNFα production but have no effect on IL-4 production. Similarly, 
replacement of estrogen at pregnancy-level concentrations in 
OVx mice suppresses T cell-mediated type IV hypersensitivity 
reaction (147, 148).
Non-obese diabetic (NOD) mice exhibit sex differences in 
the cytokine profile of islet-infiltrating CD4+ T cells, as females 
produce more IFNγ and less IL-4 than do males (149). Estrogen 
replacement in OVx NOD mice, at levels present during preg-
nancy, enhances this IFNγ production in islet infiltrates. Lambert 
et al. (150) reported similar enhancement of IFNγ production by 
ConA-activated splenic CD4+ T cells from C57BL/6 mice stimu-
lated with pregnancy-level concentrations of estrogen. Likewise, 
subcutaneous OVA sensitization in OVx C57BL/6 mice leads to 
an estrogen-dependent increase in IFNγ+ CD4+ T cells within 
the draining lymph nodes, an effect that is abrogated in ERα 
knockout mice (116). Conversely, estrogen at pregnancy concen-
trations increased the expression of IL-4 and GATA-3 in a dose-
dependent manner by CD3/CD28-cultured splenic T cells from 
C57BL/6 mice but not in those from ERα knockout mice (151). 
Concentrations of estrogen measured during pregnancy also pro-
mote FoxP3 and CD25 expression on mouse T cells in vivo and 
in vitro in an ERα-dependent manner (152). Furthermore, ERα 
expression in T cells is required for estrogen-mediated protection 
in the mouse model of EAE via the reduction of IFNγ and IL-17 
expression by CD4+ T cells (153). Indeed, patients with multiple 
sclerosis show improvement during pregnancy and this is likely 
due to elevated estrogen (154). Collectively, these findings suggest 
that concentrations of estrogen found during pregnancy enhance 
IFNγ, IL-10, and IL-4 production by CD4+ T cells and thus may 
protect the fetus against Th17-mediated immunopathology.
B CeLLS
In general, estrogen enhances B-cell maturation and antibody 
production. Cervical mucus IgA levels peak in cycling women 
prior to ovulation and are increased by oral contraceptives (155). 
Human blood mononuclear cells cultured with sheep red blood 
cells (SRBC) likewise produce more anti-SRBC antibodies in 
response to increasing doses of estrogen, an effect that is ablated 
with tamoxifen (156). Interestingly, in this model, estrogen 
was found to interfere with CD8+ T-cell suppression of B-cell 
maturation. Indeed, estrogen enhances IgG and IgM production 
in humans, and neutralization of IL-10 impairs this response 
(157, 158). B cells from patients with systemic lupus erythema-
tosus produce increased anti-dsDNA antibodies in response to 
estrogen also because of IL-10 production (159). Additionally, 
November 2015 | Volume 6 | Article 5689
Keselman and Heller Sex Differences/Estrogen in Asthma
Frontiers in Immunology | www.frontiersin.org
high concentrations of estrogen (micromolar range) increase the 
amount of antibody produced by pokeweed mitogen-stimulated 
mouse peripheral blood mononuclear cells (145). Importantly, 
estrogen and estrogenic compounds enhance IgE production by 
mouse splenocytes and thereby may contribute to allergic inflam-
mation (160).
FUTURe DiReCTiONS
To date, studies addressing the role of estrogen and other sex 
hormones in allergy and immunity have been confronted with 
major experimental limitations, resulting in a lack of consensus 
over confounding data. In  vitro experiments utilizing exog-
enous treatment of cells with agonists or antagonists to ERs are 
a good starting point but hardly address how these cells behave 
in the context of the inflamed lung in vivo. Furthermore, there 
must be a uniformity regarding the dose, duration, and deliv-
ery of estrogen treatment in either in vitro models or estrogen 
replacement in  vivo models. Exceeding normal physiological 
doses (into the micromolar range) significantly contributes to 
confounding reports as estrogen exhibits dose-specific proper-
ties and has the potential to affect an ever-growing spectrum of 
cellular pathways. There is also an inherent difficulty in gaining 
mechanistic insights from either estrogen replacement in OVx 
mice or from global ER knockout mice since there are systemic 
consequences to these animal models and allergic responses are 
complex multicellular processes. Thus, the development of more 
sophisticated mouse models is imperative to address the impact 
of estrogen on the various phases of allergic inflammation and 
on the key specific cell types in a controlled manner. For this 
purpose, the employment of inducible Cre recombinase under 
cell-specific promoters to target floxed ER alleles for knockout 
would be very helpful.
Many questions remain to be addressed regarding the role 
of estrogen in allergic inflammation. As indicated in Figure 2, 
the impact of estrogen on alveolar macrophages has been 
overlooked. Since these cells are important modulators of 
allergic lung inflammation, more attention should be focused 
on how estrogen affects their biology in the setting of allergic 
lung inflammation. The estrogen-mediated effects of changes 
in macrophage function, tissue remodeling and fibrosis, as 
well as eosinophil and monocyte recruitment are yet to be 
explored. Furthermore, the potential recruitment of inflamma-
tory monocytes and the impact of estrogen on their traffick-
ing and polarization have yet to be addressed. The respective 
contribution of ERα, ERβ, and GPR-1 to the function of innate 
and adaptive immunities in allergic inflammation needs to be 
addressed using a targeted and inducible knockout in  vivo. 
Furthermore, the potential role of ERs in steroid resistance has 
major therapeutic promise. Whether ERs interfere with GR 
signaling in hard-to-treat asthma that mostly affects women 
is unknown. Alveolar macrophages may play a role in this 
pathology, since alveolar macrophages from patients with 
asthma exhibit relative resistance to dexamethasone compared 
to healthy individuals (161–164).
CONCLUDiNG ReMARKS
Allergic disorders exhibit considerable sex-specific differences 
in prevalence, severity, age of onset, and clinical outcomes. 
These differences likely reflect the effects of sex hormones on 
the immune system, as well as other lifestyle factors. Adult 
asthma is clinically dominated by women, and the contribution 
of estrogen to this sex difference is becoming clear. However, 
the apparent lack of uniformity and consistency between experi-
mental approaches used to address this issue has led to numer-
ous confounding and conflicting results. Furthermore, asthma 
is a heterogeneous disease, and a one-size-fits-all approach 
to therapy is no longer considered reasonable. Therefore, it is 
imperative that the several different endotypes that comprise 
asthma be fully characterized and suited with appropriate rodent 
and in  vitro models that will enable us to address potential 
therapeutic avenues. The Th2 paradigm used in animal models 
needs to be reconsidered, as it addresses only 50% of clinical 
asthma. To date, the most common treatments for asthma are 
inhaled glucocorticoids for suppression of inflammatory gene 
expression and β2-adrenergic receptor agonists for inhibition 
of bronchoconstriction. Women are exceptionally burdened 
with hard-to-treat, corticosteroid-resistant, neutrophilic 
asthma (165–167). The potential interactions between estro-
gen and glucocorticoid receptors have not been addressed in 
corticosteroid-resistant asthma despite their sharing coactivator 
binding partners. Furthermore, the persistent use of glucocor-
ticoids results in significant side effects, such as cataracts and 
osteoporosis among others (168, 169). Neutralizing antibodies 
to IL-4Rα and IL-13, such as dupilumab and lebrikizumab, 
respectively, do show promise in clinical effectiveness but only 
in select patients with typical Th2-type asthma (170, 171). There 
is now an apparent shift in thinking that focuses on matching 
particular treatments to patients presenting with the appropriate 
biomarkers. This approach, however, requires extensive research 
with appropriate models. Estrogen signaling affects virtually 
every cell of the immune system. It is thus an appealing avenue 
for therapy but must certainly be carried out in a cell-specific 
and targeted manner that does not interfere with reproductive 
physiology. To achieve this goal, we must revise animal models 
to address the role of estrogen in allergic inflammation in a 
more reductionist manner. Cell-specific ER knockout models 
are essential for understanding the effect of estrogen signaling 
on a given cell type without dramatically altering the biology 
of the animal. The development of promoter-specific inducible 
CRE models permits such approaches. Such models, coupled 
with in vitro biochemical studies, may help to identify specific 
interactions between an ER isoform and a coactivator that facili-
tate enhanced allergic inflammation in women and can thus be 
targeted therapeutically.
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